lopinavir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
HIV protease inhibitors	1601	192725-17-0

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: lopinavir aluviran koletra

An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19. Molecular weight: 628.81 Formula: C37H48N4O5 CLOGP: 6.09 LIPINSKI: 2 HAC: 9 HDO: 4 TPSA: 120 ALOGS: -5.51 ROTB: 15 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2.20 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24.22 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Sept. 15, 2000	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	1154.78	22.57	568	12120	107644	46565730
Abortion spontaneous	684.30	22.57	300	12388	43346	46630028
Stillbirth	479.27	22.57	141	12547	6350	46667024
Foetal exposure during pregnancy	464.11	22.57	206	12482	30541	46642833
Abortion induced	403.96	22.57	138	12550	10122	46663252
Off label use	337.22	22.57	461	12227	379380	46293994
Viral mutation identified	309.15	22.57	77	12611	1822	46671552
Virologic failure	293.28	22.57	75	12613	1980	46671394
Maternal exposure during pregnancy	278.55	22.57	227	12461	102322	46571052
Foetal death	261.82	22.57	96	12592	8647	46664727
Premature baby	230.88	22.57	108	12580	18004	46655370
Drug resistance	216.55	22.57	102	12586	17266	46656108
Drug interaction	214.07	22.57	269	12419	202825	46470549
Immune reconstitution inflammatory syndrome	209.69	22.57	73	12615	5652	46667722
Hypomania	168.61	22.57	58	12630	4330	46669044
Pregnancy	168.42	22.57	100	12588	27037	46646337
Jaundice cholestatic	168.42	22.57	60	12628	4969	46668405
Live birth	164.59	22.57	72	12616	10258	46663116
Premature rupture of membranes	156.60	22.57	55	12633	4368	46669006
Hepatotoxicity	144.42	22.57	88	12600	24921	46648453
Premature labour	142.78	22.57	67	12621	11232	46662142
Blood HIV RNULL increased	138.00	22.57	33	12655	654	46672720
Schizophrenia	134.16	22.57	59	12629	8509	46664865
Caesarean section	129.36	22.57	71	12617	16532	46656842
Fanconi syndrome acquired	121.90	22.57	32	12656	937	46672437
Viral load increased	115.28	22.57	33	12655	1342	46672032
HIV infection	111.46	22.57	27	12661	566	46672808
Ergot poisoning	107.17	22.57	22	12666	207	46673167
Pathogen resistance	102.27	22.57	44	12644	6016	46667358
Blood bilirubin increased	99.58	22.57	79	12609	34105	46639269
Lipodystrophy acquired	99.30	22.57	30	12658	1475	46671899
CD4 lymphocytes decreased	97.31	22.57	30	12658	1580	46671794
Psychotic disorder	89.88	22.57	63	12625	22558	46650816
Treatment noncompliance	89.37	22.57	70	12618	29661	46643713
Skull malformation	87.02	22.57	20	12668	331	46673043
Spina bifida	83.87	22.57	22	12666	642	46672732
Long QT syndrome	78.24	22.57	30	12658	3050	46670324
COVID-19 pneumonia	76.45	22.57	30	12658	3245	46670129
Premature delivery	75.20	22.57	56	12632	22013	46651361
Genotype drug resistance test positive	68.40	22.57	18	12670	532	46672842
Human immunodeficiency virus transmission	68.19	22.57	13	12675	80	46673294
Immunosuppressant drug level increased	65.99	22.57	27	12661	3255	46670119
Foetal growth restriction	65.09	22.57	33	12655	6534	46666840
Trisomy 21	63.79	22.57	16	12672	389	46672985
Normal newborn	61.96	22.57	31	12657	5970	46667404
Pain	59.12	22.57	28	12660	476920	46196454
Cholelithiasis	58.64	22.57	62	12626	38619	46634755
Portal hypertension	57.81	22.57	25	12663	3458	46669916
Cushing's syndrome	57.74	22.57	17	12671	764	46672610
Cerebral ventricle dilatation	57.71	22.57	18	12670	985	46672389
COVID-19	56.38	22.57	44	12644	18531	46654843
Eosinophilia	55.05	22.57	44	12644	19173	46654201
Fatigue	52.60	22.57	53	12635	608644	46064730
Fall	51.60	22.57	13	12675	329084	46344290
Hepatic enzyme increased	51.40	22.57	85	12603	81702	46591672
Pre-eclampsia	50.96	22.57	30	12658	7964	46665410
Hyperbilirubinaemia	50.85	22.57	33	12655	10405	46662969
Drug ineffective	46.04	22.57	71	12617	677767	45995607
Hepatocellular injury	45.95	22.57	48	12640	29474	46643900
Dyspnoea	44.36	22.57	45	12643	515503	46157871
Placental disorder	44.11	22.57	16	12672	1393	46671981
Patent ductus arteriosus	42.98	22.57	21	12667	3841	46669533
Arnold-Chiari malformation	42.77	22.57	12	12676	453	46672921
Renal tubular disorder	41.92	22.57	18	12670	2447	46670927
Placenta praevia	38.75	22.57	13	12675	898	46672476
Anticoagulation drug level increased	37.69	22.57	9	12679	177	46673197
Rash maculo-papular	37.56	22.57	42	12646	27832	46645542
Neural tube defect	37.04	22.57	9	12679	191	46673183
Coarctation of the aorta	36.42	22.57	11	12677	540	46672834
Polydactyly	35.97	22.57	10	12678	365	46673009
Urinary tract infection	35.87	22.57	8	12680	220258	46453116
Vomiting	34.86	22.57	226	12462	452568	46220806
Placental insufficiency	33.93	22.57	13	12675	1318	46672056
Drug hypersensitivity	33.88	22.57	12	12676	243813	46429561
Ventricular septal defect	33.48	22.57	18	12670	4016	46669358
Pulmonary tuberculosis	33.47	22.57	19	12669	4712	46668662
Atrial septal defect	33.27	22.57	21	12667	6311	46667063
Mitochondrial cytopathy	33.24	22.57	9	12679	297	46673077
Gestational diabetes	33.15	22.57	22	12666	7197	46666177
Dysmorphism	32.67	22.57	14	12674	1893	46671481
Congenital anomaly	31.83	22.57	13	12675	1559	46671815
Electrocardiogram QT prolonged	31.76	22.57	53	12635	51272	46622102
Renal tubular acidosis	31.75	22.57	13	12675	1570	46671804
Acquired immunodeficiency syndrome	31.55	22.57	7	12681	98	46673276
Oligohydramnios	30.93	22.57	19	12669	5446	46667928
Hypertriglyceridaemia	30.18	22.57	19	12669	5685	46667689
Anaemia	29.88	22.57	143	12545	255636	46417738
Product dose omission issue	29.79	22.57	5	12683	168515	46504859
Cerebral toxoplasmosis	29.46	22.57	10	12678	716	46672658
Pain in extremity	29.28	22.57	17	12671	258663	46414711
Cardiac malposition	29.27	22.57	6	12682	56	46673318
Foetal malformation	28.93	22.57	7	12681	146	46673228
Pregnancy on contraceptive	28.90	22.57	11	12677	1096	46672278
Cholestasis of pregnancy	28.73	22.57	11	12677	1113	46672261
Maternal drugs affecting foetus	28.24	22.57	18	12670	5500	46667874
Transaminases increased	27.83	22.57	36	12652	27725	46645649
Arthralgia	27.83	22.57	35	12653	364568	46308806
Hyperlactacidaemia	27.55	22.57	13	12675	2202	46671172
Peripheral swelling	27.26	22.57	5	12683	158066	46515308
Hepatic displacement	26.63	22.57	5	12683	28	46673346
Alopecia	26.22	22.57	6	12682	162408	46510966
Congenital eye disorder	26.06	22.57	5	12683	32	46673342
Spinocerebellar disorder	25.67	22.57	5	12683	35	46673339
Mental disability	25.53	22.57	6	12682	110	46673264
Constipation	25.16	22.57	8	12680	174089	46499285
Meningomyelocele	24.81	22.57	8	12680	488	46672886
Twin pregnancy	24.72	22.57	10	12678	1171	46672203
Benign hydatidiform mole	24.71	22.57	6	12682	127	46673247
Coronavirus infection	24.69	22.57	13	12675	2781	46670593
Hypertransaminasaemia	24.65	22.57	14	12674	3474	46669900
Meningitis cryptococcal	24.60	22.57	10	12678	1185	46672189
Threatened labour	24.50	22.57	9	12679	812	46672562
Renal tubular dysfunction	24.16	22.57	7	12681	297	46673077
COVID-19 treatment	23.57	22.57	6	12682	155	46673219
Disseminated Bacillus Calmette-Guerin infection	23.30	22.57	4	12684	12	46673362
Fanconi syndrome	23.13	22.57	9	12679	951	46672423
Toxoplasmosis	23.11	22.57	10	12678	1384	46671990
Amniotic cavity disorder	23.06	22.57	4	12684	13	46673361
Hydrocephalus	22.73	22.57	15	12673	4862	46668512
Metabolic acidosis	22.60	22.57	39	12649	38741	46634633
Congenital acrochordon	22.60	22.57	5	12683	69	46673305

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	842.41	14.49	998	22378	248292	29680810
Drug interaction	579.55	14.49	742	22634	198826	29730276
Lipodystrophy acquired	570.07	14.49	179	23197	3381	29925721
Mitochondrial toxicity	430.11	14.49	133	23243	2381	29926721
Foetal exposure during pregnancy	371.29	14.49	273	23103	36598	29892504
Eyelid ptosis	325.37	14.49	130	23246	5058	29924044
Depression	300.60	14.49	361	23015	90076	29839026
Immune reconstitution inflammatory syndrome	258.26	14.49	131	23245	8970	29920132
Progressive external ophthalmoplegia	216.60	14.49	67	23309	1199	29927903
Hypertransaminasaemia	214.96	14.49	89	23287	3796	29925306
Virologic failure	196.05	14.49	79	23297	3140	29925962
Diplopia	195.19	14.49	126	23250	13646	29915456
Exposure during pregnancy	191.50	14.49	108	23268	9153	29919949
Long QT syndrome	191.03	14.49	71	23305	2262	29926840
Hypertriglyceridaemia	191.00	14.49	103	23273	7995	29921107
Fanconi syndrome acquired	183.25	14.49	67	23309	2036	29927066
Premature baby	150.90	14.49	116	23260	16575	29912527
Viral mutation identified	144.73	14.49	60	23316	2566	29926536
Drug-induced liver injury	144.20	14.49	125	23251	21149	29907953
Hepatic fibrosis	139.29	14.49	64	23312	3516	29925586
Drug effective for unapproved indication	118.44	14.49	41	23335	1058	29928044
Renal tubular disorder	99.75	14.49	57	23319	4949	29924153
Fanconi syndrome	99.31	14.49	41	23335	1734	29927368
Kaposi's sarcoma	94.21	14.49	34	23342	994	29928108
Hyperbilirubinaemia	94.05	14.49	89	23287	16853	29912249
Trisomy 21	93.94	14.49	28	23348	439	29928663
Pathogen resistance	92.98	14.49	66	23310	8344	29920758
Viral load increased	92.53	14.49	45	23331	2809	29926293
Osteoporosis	91.77	14.49	72	23304	10591	29918511
HIV infection	91.54	14.49	38	23338	1630	29927472
Death	83.37	14.49	94	23282	357189	29571913
COVID-19 pneumonia	83.30	14.49	49	23327	4491	29924611
COVID-19	73.76	14.49	80	23296	17798	29911304
Volvulus	69.90	14.49	29	23347	1242	29927860
Drug resistance	66.01	14.49	80	23296	20053	29909049
Hyperlactacidaemia	63.82	14.49	34	23342	2572	29926530
Drug ineffective	63.74	14.49	105	23271	340282	29588820
Nephropathy toxic	63.10	14.49	58	23318	10581	29918521
Congenital anomaly	62.19	14.49	27	23349	1295	29927807
Ophthalmoplegia	59.29	14.49	26	23350	1278	29927824
Hepatocellular injury	57.03	14.49	84	23292	25387	29903715
Cushing's syndrome	52.76	14.49	18	23358	444	29928658
Extraocular muscle paresis	52.72	14.49	18	23358	445	29928657
Osteoporotic fracture	51.35	14.49	22	23354	1021	29928081
Acquired immunodeficiency syndrome	50.88	14.49	18	23358	496	29928606
CD4 lymphocytes decreased	50.67	14.49	27	23349	2043	29927059
Glycosuria	49.62	14.49	23	23353	1288	29927814
Fall	49.01	14.49	42	23334	181830	29747272
Hyperlipidaemia	48.44	14.49	57	23319	13850	29915252
Loss of personal independence in daily activities	46.74	14.49	70	23306	21465	29907637
Osteonecrosis	46.32	14.49	60	23316	16075	29913027
Febrile neutropenia	46.23	14.49	13	23363	106680	29822422
HIV-associated neurocognitive disorder	45.75	14.49	15	23361	326	29928776
Electrocardiogram QT prolonged	45.61	14.49	92	23284	35743	29893359
Fatigue	45.46	14.49	116	23260	320557	29608545
Hypophosphataemia	45.14	14.49	43	23333	8202	29920900
HIV associated nephropathy	44.91	14.49	14	23362	257	29928845
Proteinuria	44.73	14.49	59	23317	16086	29913016
Lipoatrophy	44.62	14.49	17	23359	580	29928522
Portal hypertension	44.20	14.49	31	23345	3842	29925260
Product dose omission issue	43.94	14.49	9	23367	91622	29837480
Mitochondrial cytopathy	43.84	14.49	13	23363	200	29928902
Polydactyly	41.62	14.49	20	23356	1215	29927887
Osteomalacia	40.94	14.49	18	23358	890	29928212
Dyspnoea	40.31	14.49	130	23246	333165	29595937
Liver injury	40.19	14.49	49	23327	12351	29916751
Coronavirus infection	39.93	14.49	28	23348	3470	29925632
Hypotension	39.20	14.49	60	23316	200505	29728597
Cardiac failure congestive	39.03	14.49	9	23367	84398	29844704
Hepatosplenomegaly	38.50	14.49	28	23348	3673	29925429
Cerebral toxoplasmosis	38.30	14.49	20	23356	1452	29927650
Hepatitis	37.98	14.49	65	23311	22291	29906811
Pneumonia	37.97	14.49	134	23242	334172	29594930
Ventricular septal defect	37.40	14.49	27	23349	3502	29925600
Completed suicide	36.46	14.49	16	23360	99476	29829626
Peripheral swelling	36.41	14.49	3	23373	61071	29868031
CD4 lymphocytes increased	36.29	14.49	12	23364	268	29928834
Dyslipidaemia	35.48	14.49	32	23344	5695	29923407
Blood triglycerides increased	35.44	14.49	49	23327	13968	29915134
Malignant neoplasm progression	34.86	14.49	7	23369	72280	29856822
Cryptorchism	33.15	14.49	19	23357	1658	29927444
Hyperferritinaemia	32.74	14.49	12	23364	367	29928735
Blood bilirubin increased	32.00	14.49	81	23295	36555	29892547
Portal fibrosis	31.90	14.49	12	23364	395	29928707
Gastroschisis	31.75	14.49	9	23367	117	29928985
Low set ears	31.40	14.49	12	23364	413	29928689
Lipohypertrophy	30.69	14.49	11	23365	315	29928787
Adrenogenital syndrome	30.60	14.49	8	23368	75	29929027
Atypical mycobacterial infection	30.20	14.49	14	23362	784	29928318
Liver disorder	29.46	14.49	69	23307	29653	29899449
Hepatic failure	29.45	14.49	75	23301	33968	29895134
Cholestasis	29.32	14.49	62	23314	24888	29904214
Constipation	29.26	14.49	27	23349	112879	29816223
Syphilis	28.96	14.49	11	23365	372	29928730
Blood pressure increased	28.93	14.49	10	23366	71918	29857184
Kidney malformation	28.73	14.49	8	23368	97	29929005
Maternal drugs affecting foetus	28.71	14.49	25	23351	4248	29924854
Pain	27.98	14.49	58	23318	172583	29756519
Muscle spasms	27.88	14.49	8	23368	64830	29864272
Anal cancer	27.48	14.49	11	23365	429	29928673
Oesophageal candidiasis	27.02	14.49	24	23352	4186	29924916
Neonatal asphyxia	26.88	14.49	10	23366	319	29928783
Urinary tract infection	26.73	14.49	12	23364	73647	29855455
Renal failure	26.60	14.49	182	23194	128784	29800318
Disease progression	26.02	14.49	15	23361	79859	29849243
Eosinophilia	25.96	14.49	55	23321	22105	29906997
Taeniasis	25.85	14.49	7	23369	76	29929026
Blood lactic acid increased	25.64	14.49	27	23349	5803	29923299
Pneumocystis jirovecii pneumonia	25.50	14.49	47	23329	17073	29912029
Jaundice	25.48	14.49	69	23307	32417	29896685
Exomphalos	24.93	14.49	8	23368	162	29928940
Lymphadenopathy	24.60	14.49	57	23319	24319	29904783
Drug abuse	24.55	14.49	17	23359	82055	29847047
Congenital hearing disorder	24.09	14.49	7	23369	100	29929002
Stillbirth	24.05	14.49	8	23368	182	29928920
Acute kidney injury	23.96	14.49	322	23054	273520	29655582
Acute respiratory distress syndrome	23.82	14.49	55	23321	23417	29905685
Epistaxis	23.79	14.49	6	23370	52975	29876127
Adrenal suppression	23.63	14.49	11	23365	622	29928480
HIV wasting syndrome	23.53	14.49	7	23369	109	29928993
Multiple-drug resistance	23.46	14.49	19	23357	2922	29926180
Oesophageal atresia	23.34	14.49	10	23366	464	29928638
Lactic acidosis	23.19	14.49	65	23311	31148	29897954
Antiviral drug level above therapeutic	23.17	14.49	6	23370	54	29929048
Sickle cell disease	23.12	14.49	7	23369	116	29928986
Speech sound disorder	22.78	14.49	6	23370	58	29929044
Transaminases increased	22.75	14.49	54	23322	23403	29905699
Gamma-glutamyltransferase increased	22.68	14.49	62	23314	29288	29899814
Mycobacterium avium complex infection	22.66	14.49	18	23358	2693	29926409
Cortisol decreased	22.54	14.49	12	23364	906	29928196
Small for dates baby	22.02	14.49	19	23357	3189	29925913
Musculoskeletal toxicity	21.84	14.49	6	23370	69	29929033
Hepatic function abnormal	21.64	14.49	77	23299	41868	29887234
Hepatic cirrhosis	21.45	14.49	42	23334	15957	29913145
Urticaria	21.26	14.49	8	23368	54598	29874504
Inappropriate schedule of product administration	21.02	14.49	3	23373	39725	29889377
Rhabdomyolysis	20.46	14.49	101	23275	63479	29865623
Dysmorphism	20.39	14.49	15	23361	2002	29927100
Burkitt's lymphoma	20.24	14.49	7	23369	180	29928922
Encephalitis	20.15	14.49	25	23351	6411	29922691
Normal newborn	20.10	14.49	7	23369	184	29928918
Splenomegaly	20.07	14.49	37	23339	13443	29915659
Blood alkaline phosphatase increased	19.98	14.49	62	23314	31425	29897677
ADAMTS13 activity decreased	19.96	14.49	6	23370	97	29929005
Endotracheal intubation	19.91	14.49	16	23360	2434	29926668
Hyperreflexia	19.86	14.49	17	23359	2822	29926280
Castleman's disease	19.83	14.49	5	23371	40	29929062
Porphyria non-acute	19.81	14.49	9	23367	481	29928621
Cytomegalovirus chorioretinitis	19.73	14.49	18	23358	3250	29925852
Cushingoid	19.70	14.49	16	23360	2471	29926631
Faeces pale	19.65	14.49	13	23363	1464	29927638
Live birth	19.64	14.49	7	23369	197	29928905
Cachexia	19.62	14.49	25	23351	6586	29922516
Hepatomegaly	19.47	14.49	31	23345	10016	29919086
Renal tubular acidosis	19.44	14.49	14	23362	1808	29927294
Immunosuppressant drug level increased	19.31	14.49	21	23355	4681	29924421
Andersen-Tawil syndrome	19.09	14.49	4	23372	12	29929090
Blood phosphorus decreased	19.09	14.49	17	23359	2975	29926127
Hepatotoxicity	18.94	14.49	43	23333	18102	29911000
Death neonatal	18.93	14.49	8	23368	359	29928743
Back pain	18.77	14.49	32	23344	102564	29826538
Viral load decreased	18.66	14.49	5	23371	52	29929050
Opportunistic infection	18.63	14.49	12	23364	1292	29927810
Protrusion tongue	18.62	14.49	7	23369	230	29928872
Cerebral ventricle dilatation	18.34	14.49	10	23366	792	29928310
Foetal growth restriction	18.31	14.49	18	23358	3567	29925535
Feeling abnormal	18.00	14.49	11	23365	56745	29872357
Haemoglobin decreased	17.90	14.49	39	23337	114059	29815043
Somnolence	17.87	14.49	30	23346	96733	29832369
Aspartate aminotransferase increased	17.81	14.49	97	23279	63325	29865777
Progressive multifocal leukoencephalopathy	17.72	14.49	28	23348	8985	29920117
Hepatitis toxic	17.69	14.49	14	23362	2083	29927019
Hepatitis cholestatic	17.66	14.49	26	23350	7846	29921256
Pancreatitis acute	17.62	14.49	52	23324	25643	29903459
Infection	17.60	14.49	21	23355	78053	29851049
Caesarean section	17.46	14.49	14	23362	2123	29926979
Anxiety	17.40	14.49	27	23349	89844	29839258
COVID-19 treatment	17.02	14.49	7	23369	293	29928809
Prenatal screening test abnormal	17.01	14.49	4	23372	23	29929079
Renal tubular necrosis	16.88	14.49	37	23339	15214	29913888
Nephrocalcinosis	16.85	14.49	8	23368	473	29928629
Acute hepatitis C	16.77	14.49	6	23370	171	29928931
Visceral leishmaniasis	16.62	14.49	8	23368	488	29928614
Congenital abdominal hernia	16.59	14.49	4	23372	26	29929076
Red blood cell schistocytes present	16.58	14.49	7	23369	313	29928789
Transient tachypnoea of the newborn	16.51	14.49	6	23370	179	29928923
Joint swelling	16.48	14.49	8	23368	46938	29882164
Drug level increased	16.46	14.49	41	23335	18313	29910789
Ergot poisoning	16.45	14.49	5	23371	84	29929018
Immunoblastic lymphoma	16.39	14.49	3	23373	3	29929099
Cellulitis	16.38	14.49	8	23368	46776	29882326
Anogenital warts	16.36	14.49	8	23368	505	29928597
Anticoagulation drug level increased	16.24	14.49	8	23368	513	29928589
Deep vein thrombosis	16.22	14.49	14	23362	60487	29868615
Metabolic acidosis	16.20	14.49	65	23311	37396	29891706
Pneumococcal infection	15.96	14.49	7	23369	344	29928758
Drug hypersensitivity	15.90	14.49	18	23358	68501	29860601
Dizziness	15.50	14.49	89	23287	194820	29734282
Nephropathy	15.32	14.49	20	23356	5396	29923706
Psoriasis	15.30	14.49	7	23369	42499	29886603
Lymphocytic infiltration	15.28	14.49	8	23368	584	29928518
Neutrophil count decreased	15.27	14.49	7	23369	42447	29886655
Erythema	15.25	14.49	23	23353	77428	29851674
Loss of consciousness	15.22	14.49	24	23352	79351	29849751
Renal impairment	15.13	14.49	115	23261	84069	29845033
CD4 lymphocytes abnormal	14.94	14.49	5	23371	116	29928986
Lymphogranuloma venereum	14.86	14.49	3	23373	7	29929095
Segmented hyalinising vasculitis	14.80	14.49	4	23372	43	29929059
Oral candidiasis	14.76	14.49	29	23347	11042	29918060
CSF virus identified	14.72	14.49	4	23372	44	29929058
Urticarial vasculitis	14.56	14.49	4	23372	46	29929056

Pharmacologic Action:

Source	Code	Description
ATC	J05AR10	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations
FDA MoA	N0000000246	HIV Protease Inhibitors
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D044966	Anti-Retroviral Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D065692	Cytochrome P-450 CYP3A Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D017320	HIV Protease Inhibitors
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D000084762	Viral Protease Inhibitors
FDA EPC	N0000175889	Protease Inhibitor
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190107	Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
CHEBI has role	CHEBI:35660	hiv protease inhibitors
CHEBI has role	CHEBI:36044	anti-virus drug
CHEBI has role	CHEBI:149553	anti-coronaviral agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Coronavirus infection	off-label use	186747009
Prevention of HIV Infection after Exposure	off-label use
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Cirrhosis of liver	contraindication	19943007	DOID:5082
Complete atrioventricular block	contraindication	27885002
Hereditary factor VIII deficiency disease	contraindication	28293008	DOID:12134
Torsades de pointes	contraindication	31722008
Hereditary factor IX deficiency disease	contraindication	41788008	DOID:12259
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Chronic type B viral hepatitis	contraindication	61977001
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Cardiomyopathy	contraindication	85898001	DOID:0050700
Prolonged QT interval	contraindication	111975006
Chronic hepatitis C	contraindication	128302006
Structural disorder of heart	contraindication	128599005
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Second degree atrioventricular block	contraindication	195042002
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Mixed hyperlipidemia	contraindication	267434003
Hypertriglyceridemia	contraindication	302870006
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Congenital long QT syndrome	contraindication	442917000
First Degree Atrioventricular Heart Block	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.03	acidic
pKa2	12.72	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.99		CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.07		CHEMBL
Pol polyprotein	Enzyme		Q72874_9HIV1	INHIBITOR	Ki	10.40		CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1BR					WOMBAT-PK
CAAX prenyl protease 1 homolog	Enzyme		FACE1_MOUSE		IC50	4.74		CHEMBL
Protease	Enzyme		Q9YQ12_9HIV1		IC50	7.60		CHEMBL

External reference:

ID	Source
4021228	VUID
N0000179581	NUI
D01425	KEGG_DRUG
4021228	VANDF
C0674432	UMLSCUI
CHEBI:31781	CHEBI
AB1	PDB_CHEM_ID
CHEMBL729	ChEMBL_ID
92727	PUBCHEM_CID
D061466	MESH_DESCRIPTOR_UI
DB01601	DRUGBANK_ID
11504	IUPHAR_LIGAND_ID
7798	INN_ID
2494G1JF75	UNII
195088	RXNORM
15774	MMSL
d04716	MMSL
008874	NDDF
129475001	SNOMEDCT_US
387067003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-0522	TABLET, FILM COATED	100 mg	ORAL	NDA	26 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-1575	TABLET, FILM COATED	100 mg	ORAL	NDA	26 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-2605	TABLET, FILM COATED	200 mg	ORAL	NDA	26 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-3956	SOLUTION	80 mg	ORAL	NDA	26 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-6799	TABLET, FILM COATED	200 mg	ORAL	NDA	26 sections
Lopinavir-Ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	0527-1947	SOLUTION	80 mg	ORAL	ANDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	11819-342	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	21695-362	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Lopinavir and ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	31722-556	TABLET, FILM COATED	200 mg	ORAL	ANDA	27 sections
Lopinavir and ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	31722-603	TABLET, FILM COATED	100 mg	ORAL	ANDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	53808-0276	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5566	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	55289-947	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Lopinavir and Ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	65015-299	GRANULE	40 mg	ORAL	Export only	1 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	66336-624	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	68071-2348	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	68258-1972	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	70518-0091	TABLET, FILM COATED	200 mg	ORAL	NDA	26 sections